Yehuda Handelsman
Endocrinology, Diabetes & Metabolism · Tarzana, CANPI 1063453769
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Novo Nordisk at 29.7% of the total. Reporting peaked in 2019 at $362,102 and has fallen 56.8% since, to $156,462 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,007 payments — averaging $1027.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$307K
- Sanofi-aventis U.S. LLC$163K
- AstraZeneca$121K
- Amgen$89K
- Regeneron$58K
- Boehringer Ingelheim$57K
- plus $239K from 44 others
Across 136 payments — averaging $2831.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$142K
- Amgen$74K
- Novo Nordisk AS$56K
- Applied Therapeutics, Inc.$38K
- Sanofi US Services Inc.$35K
- Astrazeneca UK Limited$14K
- plus $26K from 4 others
What the payments were for
- Consulting fees$320,25931%
- Speaking & faculty fees$556,11354%
- Travel & lodging$128,54912%
- Food & beverage$29,1943%
- Education$1740%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$186,170
- SOLIQUA 100/33$82,138
- Repatha$71,672
- FARXIGA$67,225
- RYBELSUS$61,295
- NEXLETOL$46,999
- NEXLIZET$46,769
- Korlym$38,954
- TOUJEO$36,424
- NO PRODUCT DISCUSSED$35,250
- JARDIANCE$33,855
- Vascepa$22,935
- Tresiba$18,703
- INVOKANA$17,956
- PRALUENT$16,974
- STEGLATRO$15,949
- EVKEEZA$14,775
- SOTAGLIFLOZIN$14,737
- Thyquidity$8,700
- WIDAPLIK$7,297
How this compares
$1,034,349 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $62,375 |
| FarxigaDapagliflozin Propanediol | 18 | $22,066 |
| RybelsusSemaglutide | 11 | $19,302 |
| TradjentaLinagliptin | 29 | $18,763 |
| JardianceEmpagliflozin | 14 | $17,859 |
| MounjaroTirzepatide | 15 | $17,743 |
| VascepaIcosapent Ethyl | 15 | $5,214 |
| SynthroidLevothyroxine Sodium | 19 | $1,757 |
| Rosuvastatin Calcium | 42 | $921 |
| Olmesartan Medoxomil | 20 | $437 |
| Levothyroxine Sodium | 34 | $313 |
| Atorvastatin Calcium | 57 | $307 |
| Metformin Hcl | 36 | $275 |
| Ezetimibe | 24 | $257 |
| Eszopiclone | 11 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $306,956 | $81,67849 claims |
| Boehringer IngelheimTradjenta, Jardiance | $56,869 | $36,62143 claims |
| AstraZenecaFarxiga | $121,095 | $22,06618 claims |
| Lilly USA, LLCMounjaro | $6,138 | $17,74315 claims |
| AbbVieSynthroid | $328 | $1,75719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Tarzana
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
- Athena Philis-Tsimikasla Jolla$574K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.